Order Article Reprints

Shimose S, Iwamoto H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Kuromatsu R, et al. Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Cancers. 2020; 12(7):1867. https://doi.org/10.3390/cancers12071867

Shimose, Shigeo, Hideki Iwamoto, Takashi Niizeki, Tomotake Shirono, Yu Noda, Naoki Kamachi, Shusuke Okamura, Masahito Nakano, Hideya Suga, Ryoko Kuromatsu, and et al. 2020. "Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study" Cancers 12, no. 7: 1867. https://doi.org/10.3390/cancers12071867

Shimose, S., Iwamoto, H., Niizeki, T., Shirono, T., Noda, Y., Kamachi, N., Okamura, S., Nakano, M., Suga, H., Kuromatsu, R., Yamaguchi, T., Kawaguchi, T., Tanaka, M., Noguchi, K., Koga, H., & Torimura, T. (2020). Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Cancers, 12(7), 1867. https://doi.org/10.3390/cancers12071867